Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Martina Di Modica
Observed names:
Di Modica M.,
Di Modica, Martina,
Martina D. Modica,
Martina Modica
Institution:
Fondazione IRCCS Istituto Nazionale dei Tumori
Observed institutions:
University of East Anglia,
Norwich Research Park,
Istituto di Biomedicina e di Immunologia Molecolare Alberto Monroy,
National Cancer Institute,
Center for Cancer Research,
National Research Council,
Fondazione IRCCS Istituto Nazionale dei Tumori
show all 7
ORCID:
0000-0001-6320-5247
Observed ORCID:
0000-0001-6320-5247
OpenAlex ID:
A5072166447
Works
29
Awards
1
Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment
2021
·
Khiem C. Lam
, Romina E. Araya
, et al.
·
Cell
·
648
Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
2021
·
Martina Di Modica
, Giorgio Gargari
, et al.
·
Cancer Research
·
207
PDF
Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers
2016
·
Martina Di Modica
, Viola Regondi
, et al.
·
Cancer Letters
·
168
PDF
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
2018
·
Tiziana Triulzi
, Luca Forte
, et al.
·
OncoImmunology
·
111
PDF
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
2018
·
Tiziana Triulzi
, Viola Regondi
, et al.
·
British Journal of Cancer
·
100
The Emerging Role of the Microbiota in Breast Cancer Progression
2023
·
Giancarla Bernardo
, Valentino Le Noci
, et al.
·
Cells
·
93
PDF
Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth
2021
·
Alastair M. McKee
, Benjamin M. Kirkup
, et al.
·
iScience
·
90
Reduction of Staphylococcus epidermidis in the mammary tumor microbiota induces antitumor immunity and decreases breast cancer aggressiveness
2022
·
Giancarla Bernardo
, Valentino Le Noci
, et al.
·
Cancer Letters
·
69
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
2015
·
Martina Di Modica
, Lucia Sfondrini
, et al.
·
Oncotarget
·
52
PDF
Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells
2018
·
Giuseppa Augello
, Martina Modica
, et al.
·
Cell Death and Disease
·
44
PDF
Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
2017
·
Martina Di Modica
, Elda Tagliabue
, et al.
·
Disease Markers
·
37
PDF
The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
2022
·
Martina Di Modica
, Valeria Arlotta
, et al.
·
Frontiers in Oncology
·
36
PDF
Maspin influences response to doxorubicin by changing the tumor microenvironment organization
2013
·
Tiziana Triulzi
, Manuela Ratti
, et al.
·
International Journal of Cancer
·
15
HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer
2022
·
Tiziana Triulzi
, Viola Regondi
, et al.
·
Cancers
·
6
PDF
Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumour growth via a mast cell-dependent pathway
2020
·
Benjamin M. Kirkup
, Alastair M. McKee
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
6
PDF
Gut Microbiota and Trastuzumab Response in HER2- Positive Breast Cancer
2020
·
Di Modica, Martina
·
Open Research Online (The Open University)
·
4
Computational modeling of lesion dynamics in HER2+ breast cancer: integrating gut microbiota diversity into therapy response prediction
2026
·
Maria Valeria De Bonis
, Tiziana Triulzi
, et al.
·
Research Square
·
1
PDF
Abstract P4-10-32: Commensal gut microbiota influences efficacy of trastuzumab in patients with HER2-positive breast carcinoma
2020
·
Elda Tagliabue
, Martina Di Modica
, et al.
·
Cancer Research
·
1
Abstract 4959: The gut microbiota contributes to the effectiveness of HER2-targeted therapy
2019
·
Martina Di Modica
, Viola Regondi
, et al.
·
Immunology
·
1
Abstract 4959: The gut microbiota contributes to the effectiveness of HER2-targeted therapy
2019
·
Martina Di Modica
, Viola Regondi
, et al.
·
Cancer Research
·
1
Data from Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
2023
·
Martina Di Modica
, Giorgio Gargari
, et al.
Supplementary Data from Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
2023
·
Martina Di Modica
, Giorgio Gargari
, et al.
Supplementary Tables from Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
2023
·
Martina Di Modica
, Giorgio Gargari
, et al.
Supplementary Tables from Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
2023
·
Martina Di Modica
, Giorgio Gargari
, et al.
Data from Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer
2023
·
Martina Di Modica
, Giorgio Gargari
, et al.
Show more works
View as search
Works count:
29
Citation count:
1,690
H-index:
13
I10-index:
13
Year
Topic
Type